© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
Anticoagulants
Anticoagulants Improve Survival Rates in Patients With COVID-19
June 01, 2020
Researchers from the Mount Sinai COVID Informatics Center report improved survival rates in COVID patients treated with anticoagulants.
Time of Day for Taking Warfarin Does Not Affect Anticoagulation Stability
January 27, 2020
Administration time for warfarin did not affect the stability of the drug’s anticoagulation effect, a new study showed.
Crizanlizumab for Sickle Cell Pain Reduction Approved by FDA
November 15, 2019
First and currently only biological targeting P-selectin.
Wilate Approved for Hemophilia A Treatment
October 09, 2019
Also indciated to control bleeding and perioperative management.
New Warnings for Tofacitinib Issued by FDA
July 29, 2019
Black box warns of increased risk of blood clots and death.
Study: VKAs Better Protect Aortic Valve Replacement Patients
June 14, 2019
Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.
AF Patients Taking OACs Have Lower Dementia Risk
June 14, 2019
Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.
DOAC Use Increasing in Nursing Homes
May 24, 2019
The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.
Atrial Fibrillation Patients Often Overestimate Stroke and Bleeding Risks
May 24, 2019
Overestimating the bleeding risk of anticoagulants may lead to poor compliance.
FDA Approves Fragmin as First Pediatric Anticoagulant Treatment
May 16, 2019
Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.
Bleeding Improved with Apixaban versus VKA
April 22, 2019
Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.
Kidney Disease Patients May Not Be Getting OACs
April 22, 2019
Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.
Patients with Cognitive Impairment Less Likely to Get OACs
March 15, 2019
Study finds different anticoagulation treatment levels for patients with cognitive problems.
Two Studies Show Efficacy of Rivaroxaban, Other NOACs in Preventing Stroke
March 15, 2019
A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.
Increased Risk of Blood Clots and Death Seen with Higher Dose Tofacitinib
February 26, 2019
Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.
Cablivi for Acquired Thrombotic Thrombocytopenic purpura
February 18, 2019
What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.
Study: DOACs Equal to or Better Than Warfarin
February 16, 2019
DOACs are as good as warfarin in preventing atrial fibrillation complications.
New Guidelines: NOACs Preferred Over Warfarin in AFib
February 16, 2019
Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.
Racial Disparities Found in Oral Anticoagulant Prescription Patterns
January 14, 2019
Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.
Choice of Anticoagulant and Cotherapy with a PPI Affect Gastrointestinal Bleeding Risk
January 11, 2019
The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.